ALERGOLOGÍA PARA MÉDICOS Y PACIENTES 2021

Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Authors: Valent P1, Akin C2, Bonadonna P3, Hartmann K4, Brockow K5, Niedoszytko M6, Nedoszytko B7, Siebenhaar F8, Sperr WR9, Oude Elberink JNG10, Butterfield JH11, Alvarez-Twose I12, Sotlar K13, Reiter A14, Kluin-Nelemans HC15, Hermine O16, Gotlib J17, Broesby-Olsen S18, Orfao A19, Horny HP20, Triggiani M21, Arock M22, Schwartz LB23, Metcalfe DD24. 1 Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at. 2 Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich. 3 Allergy Unit, Verona University Hospital, Verona, Italy. 4 Department of Dermatology, University of Luebeck, Luebeck, Germany. 5 Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany. 6 Department of Allergology, Medical University

Wheat allergy: diagnosis and management. Authors: Cianferoni A1. 1 Department of Pediatrics, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, PA, USA. Abstract: Triticum aestivum (bread wheat) is the most widely grown crop worldwide. In genetically predisposed individuals, wheat can cause specific immune responses. A food allergy to wheat is characterized by T helper type 2 activation which can result in immunoglobulin E (IgE) and non-IgE mediated reactions. IgE mediated reactions are immediate, are characterized by the presence of wheat-specific IgE antibodies, and can be life-threatening. Non-IgE mediated reactions are characterized by chronic eosinophilic and lymphocytic infiltration of the gastrointestinal tract. IgE mediated responses to wheat can be related to wheat ingestion (food allergy) or wheat inhalation (respiratory allergy). A food allergy to wheat is more common in children and can be associated with a severe reaction such as an

SJS/NET  Dr. Andrés Puerto

Hypersensitivity pneumonitis: A fibrosing alveolitis produced by inhalation of diverse antigens Authors: Greenberger PA1. 1 Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: p-greenberger@northwestern.edu. Abstract: Hypersensitivity pneumonitis (HP) is a TH1 lymphocyte-biased fibrosing alveolitis caused by antigens ranging from avian excreta, fungi, thermophilic bacteria, and protozoa to reactive chemicals found in the workplace. Mimicking a viral syndrome, acute exposures to inciting antigens cause abrupt onset of nonproductive cough, dyspnea, and chills with arthralgias or malaise usually from 4 to 8 hours later so that the temporal relationship between antigen exposure and symptoms might be unsuspected. The histology of HP reveals prominent lymphocyte infiltrates that thicken the alveolar septa with poorly formed granulomas or giant cells. Bronchoalveolar lavage fluid demo

Therapeutic strategy according to the differing patient response profiles to omalizumab in chronic spontaneous urticaria. Authors:  Giménez Arnau AM1, Valero Santiago A2, Bartra Tomás J3, Jáuregui Presa I4, Labrador-Horrillo M5, Miquel Miquel FJ6, Ortiz de Frutos J7, Sastre J8, Silvestre Salvador FJ9, Ferrer Puga M10. 1 Dermatology Department. Hospital del Mar. Institut Mar D´Investigacions Mèdiques. Universitat Autónoma de Barcelona, Barcelona (Spain). 2 Allergy Unit. Pneumology Department. Hospital Clínic, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona (Spain). RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL). 3 Allergy Unit. Pneumology Department. Hospital Clínic. Barcelona. Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona (Spain). RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL). 4 Allergy Department. Hospital Universitario Basurto, Bilbao (Spain). 5 Allergology Department. Hospital Universitari

Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years Authors:  Dumas O1, Hasegawa K2, Mansbach JM3, Sullivan AF2, Piedra PA4, Camargo CA Jr2. 1 INSERM, U1168, VIMA: Aging and Chronic Diseases, Epidemiological and Public Health Approaches, F-94807, Villejuif, France; Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux, France. Electronic address: orianne.dumas@inserm.fr. 2 Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 3 Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Mass. 4 Departments of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, Tex. Abstract: BACKGROUND: A better understanding of bronchiolitis heterogeneity might help clarify its relationship with the development of recurrent wheezing and asthma. OBJECTIVES: We sought to identify severe bronchiolitis profiles using a cl

Non-celiac gluten or wheat sensitivity: It's complicated! Authors:   Pinto-Sanchez MI1, Verdu EF1. 1 Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. Abstract: In the last 30 years, non-celiac gluten sensitivity (NCGS) has emerged as an intriguing and controversial topic in gastroenterology. The diagnosis of NCGS/NCWS requires a symptomatic reaction to gluten, or wheat-containing food, and remission of symptoms with gluten or wheat challenge, in patients in whom celiac disease and wheat allergy have been excluded. There have been several randomized clinical trials (RCT) addressing this issue which have produced controversial results. In this issue of Neurogastroenterology and Motility, a double-blind placebo-controlled randomized trial in patients with suspected NCGS on GFD, did not reproduce symptoms after gluten intake compared to placebo. This mini-review addresses outstanding issues related to the diagnosis of NCGS/NCWS

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. Authors: Serra E1, Campo C2, Novák Z3, Majorek-Olechowska B4, Pulka G5, García-Bea A6, Labeaga L6. 1 a Dermatology Service , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain. 2 b Clinical Research Department , FAES FARMA S. A. , Bizkaia , Spain. 3 c Department of Pediatrics , University of Szeged , Szeged , Hungary. 4 d Alergo-Med. Specjalistyczna Przychodnia Lekarska , Tarnów , Poland. 5 e Specjalistyczny Ooerodek "All-Med" , Kraków , Poland. 6 f Medical Department , FAES FARMA S. A. , Bizkaia , Spain. Abstract: PURPOSE: To evaluate the efficacy/safety of bilastine in pruritus relief in patients with chronic spontaneous urticaria (CSU) or other pruritic skin diseases. METHODS: In this multicenter, open-label, exploratory study (EudraCT No.: 2016-001505-17), 115 adults with CSU (n = 34), eczema/dermatit

Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. Authors:   Pavord ID1, Hanania NA2. 1 Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: ian.pavord@ndm.ox.ac.uk. 2 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas. Abstract: There have been major advances in the assessment and management of severe asthma over the last 10 years. As a result, many patients with severe asthma have new, targeted biological treatment options. These biologic therapies are only effective in subgroups (phenotypes) of patients defined using clinical parameters and biomarkers. All biologic therapies approved at the moment target type 2 high or eosinophilic airway inflammation. We use a case-based discussion approach to discuss biological treatment options for a patient presenting with severe eos

Diagnosing Peanut Allergy with Fewer Oral Food Challenges. Authors:  Koplin JJ1, Perrett KP2, Sampson HA3. 1 Population Allergy Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia. 2 Population Allergy Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia; Departments of Allergy and Immunology and General Medicine, Royal Children's Hospital, Parkville, Victoria, Australia. 3 Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: hugh.sampson@mssm.edu. Abstract: Diagnosis of peanut allergy presents a significant clinical challenge. Accurate diagnosis is critical for patient management and prevention of allergic reactions, whereas overdiagnosis or failure to diag

Alergia a epitelios (Dr. Jaime Sosa Moreno)

Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Authors:   Vrijlandt EJLE1, El Azzi G2, Vandewalker M3, Rupp N4, Harper T5, Graham L6, Szefler SJ7, Moroni-Zentgraf P8, Sharma A9, Vulcu SD10, Sigmund R11, Chawes B12, Engel M2, Bisgaard H13. 1 Department of Pediatric Pulmonology and Pediatric Allergy, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 2 TA Respiratory Diseases, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 3 Clinical Research of the Ozarks, Columbia, MO, USA. 4 National Allergy and Asthma Research, North Charleston, SC, USA. 5 Charleston Allergy and Asthma, Charleston, SC, USA. 6 Children's Healthcare of Atlanta, Atlanta, GA, USA. 7 Department of Pediatrics Breathing Institute and Pediatric Pulmonary Section, Children's Hospital of Colorado and the Universit

Testimonio de paciente en tratamiento con inmunoterapia alérgeno-específica

Urticaria and Angioedema: an Update on Classification and Pathogenesis. Authors:  Radonjic-Hoesli S1, Hofmeier KS2, Micaletto S3, Schmid-Grendelmeier P3, Bircher A2, Simon D4. 1 Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. Susanne.radonjic@insel.ch. 2 Department of Dermatology, Allergy Unit, University Hospital Basel, 4031, Basel, Switzerland. 3 Department of Dermatology and Allergy, University Hospital Zurich, 8091, Zurich, Switzerland. 4 Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland. Dagmar.simon@insel.ch. Abstract:  Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has increasingly attracted notice to clinicians and researchers, last but not least inspired by the approval of omalizumab, an anti-IgE antibody, for urticaria treatment. There is wide consensus on the clinic

Severe Asthma in Childhood Authors: Angela Marko, DO a, Kristie R. Ross, MD, MS b. a Division of Pediatric Pulmonology, University Hospitals Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, USA b Division of Pediatric Pulmonology, University Hospitals Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA Abstract:  Severe asthma in childhood is a heterogeneous condition, but is broadly defined as asthma that requires a high level of therapy to achieve control. Asthma phenotypes and endotypes are important to stratify clinical features, underlying pathophysiological mechanisms, and treatment responses and are essential to guide future therapeutic development. Management of a child with severe asthma requires a detailed multidisciplinary assessment. DOI:   https://doi.org/10.1016/j.iac.2018.12.007

The Consortium for Food Allergy Research (CoFAR): The first generation. Authors:  Sampson HA1, Berin MC1, Plaut M2, Sicherer SH1, Jones S3, Burks AW4, Lindblad R5, Leung DYM6, Wood RA7. 1 Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, New York, NY. 2 National Institutes of Health/National Institutes of Allergy and Infectious Diseases, Bethesda, Md. 3 Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark. 4 Department of Pediatrics, University of North Carolina, Chapel Hill, NC. 5 Emmes Corporation, Rockville, Md. 6 Department of Pediatrics, National Jewish Health, Denver, Mass. 7 Department of Pediatrics at the Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: rwood@jhmi.edu. Abstract:  The Consortium for Food Allergy Research (CoFAR) was established by the National Institute of Allergy and Infectious Diseases in 2005 as a collaborative res

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. Authors:  Kaplan A1, Ferrer M2, Bernstein JA3, Antonova E4, Trzaskoma B5, Raimundo K5, Rosén K5, Omachi TA5, Khalil S6, Zazzali JL5. 1 Medical University of South Carolina, Charleston, SC. 2 Clinica Universidad de Navarra, Universidad de Navarra, Instituto De Investigación sanitaria de Navarra (IDISNA) Pamplona, Pamplona, Spain. 3 University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio. 4 Genentech, Inc, South San Francisco, Calif. Electronic address: antonova.evgeniya@gene.com. 5 Genentech, Inc, South San Francisco, Calif. 6 Novartis AG, Basel, Switzerland. Abstract:  BACKGROUND: Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. OBJECTIVE: We sought to describe response patterns by using data from the 3

Asthma, rhinitis, and nasal polyp multimorbidities. Authors:  Castillo Vizuete JA1, Sastre J2, Del Cuvillo Bernal A3, Picado C4, Martínez Moragón E5, Ignacio García JM6, Cisneros Serrano C7, Álvarez Gutiérrez FJ8, Mullol Miret J9. 1 Servicio de Neumología, Hospital Universitario Quirón Dexeus, Barcelona. Coordinador Grupo de Rinitis, Área de Asma SEPAR, Barcelona, España. Electronic address: jacastillovizuete@gmail.com. 2 Servicio de Alergología, Fundación Jiménez Díaz; CIBERES, Madrid, España. 3 Servicio de Otorrinolaringología, Hospital de Jerez, Jerez de la Frontera, Cádiz, España. 4 Universitat de Barcelona; IDIBAPS, CIBERES, Barcelona, España. 5 Servicio de Neumología, Hospital Universitario Dr. Peset, Valencia, España. 6 Servicio de Neumología, Grupo Hospitalario Quirón, Marbella, Marbella, Málaga, España. 7 Servicio de Neumología, Hospital Universitario La Princesa, Madrid, España. 8 Servicio de Neumología, Hospital Virgen del Rocío, Sevilla, España. 9 Immumoal·l